In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

This comes after both Maccabi and Meuhedet Health Services announced the same subsidy for the Mounjaro weight loss shot.

However, the real success is reflected in the national obesity rate ... on the market that the FDA has specifically approved ...

Despite the success, both companies have struggled to ... individuals lose significant amounts of weight. For instance, Wegovy—the leading drug in this category—has shown weight loss results ...